| Identification | Back Directory | [Name]
Acetamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-N-(tetrahydro-2H-pyran-4-yl)- | [CAS]
2296821-50-4 | [Synonyms]
N-[4-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-N-(tetrahydro-2H-pyran-4-yl)acetamide
Acetamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-N-(tetrahydro-2H-pyran-4-yl)- | [Molecular Formula]
C24H33N5O3 | [MOL File]
2296821-50-4.mol | [Molecular Weight]
439.55 |
| Chemical Properties | Back Directory | [Boiling point ]
696.2±55.0 °C(predicted) | [density ]
1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
6.66±0.30(predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC)[1]. | [in vivo]
BNT411 (3 mg/kg; i.v.; 8 times with 4 to 5 days interval) demonstrates antitumor activity in mouse tumor models[1]. | [References]
[1] Ugur Sahin, et al. Tlr7 agonist and combinations for cancer treatment. WIPO. WO2023083868. 2023-05-19 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|